Endocrinology Medical News about Diabetes Mellitus Diabetes Mellitus, Type 2

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Cytarabine Plus Methotrexate Improves Remission Rates in Patients with Primary CNS Lymphoma

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Hitting Chronic Lymphocytic Leukemia Where it Hurts

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
Diabetes, Obesity and Metabolism, 11/06/09

Blonde L et al. – Liraglutide is a new glucagon–like peptide–1 (GLP–1) receptor agonist and a true GLP–1 analogue. After successful phase 2 studies, liraglutide was assessed in a series of phase 3 trials. Liraglutide was associated with a low risk of hypoglycaemia and was generally well tolerated. The majority of adverse effects were gastrointestinal, the most frequent of which was nausea.

<< Previous
Misclassifying nonexempt employees as exempt can cost you

Next >>
Androgen Replacement Therapy in Turner Syndrome: A Pilot Study